Teva Pharmaceuticals (TEVA.TA) stock price, revenue, and financials

Teva Pharmaceuticals market cap is ₪3.5 t, and annual revenue was $16.66 b in FY 2020

₪3.5 T

TEVA.TA Mkt cap, 29-Jul-2021

$16.7 B

Teva Pharmaceuticals Revenue FY, 2020
Teva Pharmaceuticals Gross profit (FY, 2020)7.7 B
Teva Pharmaceuticals Gross profit margin (FY, 2020), %46.4%
Teva Pharmaceuticals Net income (FY, 2020)-4.1 B
Teva Pharmaceuticals EBIT (FY, 2020)-3.6 B
Teva Pharmaceuticals Cash, 31-Dec-20202.2 B
Teva Pharmaceuticals EV3.5 T
Get notified regarding key financial metrics and revenue changes at Teva PharmaceuticalsLearn more
Banner background

Teva Pharmaceuticals Revenue

Teva Pharmaceuticals revenue was $16.66 b in FY, 2020

Embed Graph

Teva Pharmaceuticals Revenue Breakdown

Embed Graph

Teva Pharmaceuticals revenue breakdown by geographic segment: 54.8% from North America, 30.8% from Europe and 14.4% from International Markets

Teva Pharmaceuticals Income Statement

Teva Pharmaceuticals Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

963.0m1.8b2.0b2.2b

Accounts Receivable

7.1b5.8b5.7b4.6b

Prepaid Expenses

1.1b899.0m870.0m945.0m

Inventories

4.9b4.7b4.4b4.4b

Current Assets

15.4b13.8b13.5b13.0b

PP&E

7.7b6.9b6.4b6.3b

Goodwill

28.4b24.9b24.8b20.6b

Total Assets

70.6b60.7b57.5b50.6b

Accounts Payable

2.1b1.9b1.7b1.8b

Short-term debt

3.6b2.2b2.3b3.7b

Current Liabilities

17.9b14.3b13.7b13.2b

Long-term debt

28.8b26.7b25.0b23.2b

Non-Current Liabilities

33.9b30.6b28.7b26.4b

Total Debt

32.5b28.9b27.3b26.9b

Total Liabilities

51.9b44.9b42.4b39.6b

Common Stock

54.0m56.0m56.0m57.0m

Preferred Stock

3.6b

Additional Paid-in Capital

23.5b27.2b27.3b27.4b

Retained Earnings

(3.8b)(6.0b)(7.0b)(10.9b)

Total Equity

18.7b15.8b15.1b11.1b

Debt to Equity Ratio

1.7 x1.8 x1.8 x

Debt to Assets Ratio

0.5 x0.5 x0.5 x

Financial Leverage

3.8 x3.8 x3.8 x4.6 x

Teva Pharmaceuticals Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(16.4b)(2.5b)(1.0b)(4.1b)

Depreciation and Amortization

2.1b1.8b1.7b1.6b

Accounts Receivable

514.0m88.0m(394.0m)

Inventories

199.0m26.0m271.0m(41.0m)

Accounts Payable

(1.8b)(500.0m)643.0m

Cash From Operating Activities

3.5b2.4b748.0m1.2b

Purchases of PP&E

(874.0m)(651.0m)(525.0m)(578.0m)

Cash From Investing Activities

2.2b1.9b1.4b863.0m

Short-term Borrowings

(1.7b)(260.0m)(2.0m)(559.0m)

Long-term Borrowings

(3.3b)(7.4b)(3.9b)(1.9b)

Dividends Paid

(1.2b)(22.0m)(52.0m)

Cash From Financing Activities

(5.7b)(3.4b)(1.9b)(1.9b)

Net Change in Cash

(25.0m)819.0m193.0m202.0m

Interest Paid

795.0m815.0m840.0m846.0m

Income Taxes Paid

106.0m420.0m552.0m709.0m

Teva Pharmaceuticals Ratios

USDFY, 2017

Revenue/Employee

432.2k

Debt/Equity

1.7 x

Debt/Assets

0.5 x

Financial Leverage

3.8 x

P/E Ratio

(1.2)

Teva Pharmaceuticals Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Facilities

889090

Facilities (United States)

17

Facilities (Europe)

333134

Facilities (Rest of World)

38

Facilities (North America)

2119

Facilities (International Markets)

3837

Products Launched (United States)

40

Products Launched (North America)

2343

Products Applications (United States)

343297251

Tentative Approvals (United States)

849279

Generic Approvals (Europe)

1.13 k734660

Marketing Authorization Applications (Europe)

1.76 k1.27 k1.08 k

Trials Products Approved (Neurology and Neuropsychiatry)

2

Phase III Trials Products (Neurology and Neuropsychiatry)

2

Phase II Trials Products (Neurology and Neuropsychiatry)

3

Trials Products Submitted (Migraine and Other Pain)

1

Phase III Trials Products (Migraine and Other Pain)

2

Phase II Trials Products (Migraine and Other Pain)

3

Trials Products Approved (Respiratory)

322

Trials Products Submitted (Respiratory)

11

Phase III Trials Products (Respiratory)

11

Trials Products Under Regulatory Review (Respiratory)

2

Phase III Trials Products (CNS, Neurology and Neuropsychiatry)

33

Phase III Trials Products (Migraine and Pain)

31

Phase II Trials Products (Migraine and Pain)

12

Trials Products Approved (Oncology)

22

Finished Dosage and Packaging Manufacturing Facilities

4069625547

Sterile Units Produced

700 m720 m720 m650 m753 m

Tablets and Capsules Produced

61 b88 b88 b80 b73 b

Active Pharmaceutical Ingredients Production Facilities

2020181817

Patents and Patent Applications (Active Pharmaceutical Ingredients)

600650

Teva Pharmaceuticals Sustainability Metrics

 FY, 2019

Water Withdrawn (Surface Water)

446 megaliters

Water Withdrawn (Other Suppliers)

6.22 k megaliters

Water Withdrawn (Ground Water)

1.73 k megaliters

Water Discharged (Surface Water)

2.26 k megaliters

Water Discharged (Other)

4.09 k megaliters

Water Discharged (Groundwater)

79 megaliters

Water Consumed

1.83 k megaliters

Waste Recycled, percent

38%

Waste Recycled

56.1 k tons

Waste Landfilled

11.95 k tons

Waste Incinerated

36.22 k tons

Waste Disposed (Bio Treatment)

44.44 k tons

Total Waste Landfilled

11.95 k tons

Total Waste

148.71 k tons

Total Recordable Injury Rate

0.34

Purchased Energy Used (Steam)

77.37 k MWh

Purchased Energy Used (Direct Heating/Cooling)

2.8 k MWh

Occupational Disease Rate

0.02

Number of Occupational Diseases

9

Number of Injuries and Illness

130

Nonhazardous Waste Generated

54.51 k tons

Lost Time Days

1.51 k

Lost Day Rate

0.18

Hazardous Waste Generated

94.19 k tons

Greenhouse Gas Emissions Intensity

18.93 metric tons of carbon dioxide equivalent per full-time equivalent employees

Greenhouse Gas Emissions (Scope 2)

404.5 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1)

339.3 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1 and Scope 2)

743.8 k metric tons of carbon dioxide equivalent

Energy Used from Renewable Energy Sources (Biomass)

12.82 k MWh

Energy Used (Propane)

15.24 k MWh

Energy Used (Electricity, Grid Electricity)

808.57 k MWh

Energy Purchased (Renewable Electricity)

421.41 k MWh

Energy Consumption (Petrol - Mobile)

124.71 k MWh

Energy Consumption (Natural Gas)

1.15 m MWh

Energy Consumption (Lliquid Petroleum Gas)

48.82 k MWh

Energy Consumption (Kerosene)

2.74 k MWh

Energy Consumption (Fuel Oil)

154.32 k MWh

Energy Consumption (Diesel)

23.12 k MWh

Energy Consumption (Diesel - Mobile)

82.29 k MWh

Energy Consumption

2.92 m MWh

Electricity Used from Renewable Energy Sources

561 MWh

Teva Pharmaceuticals Human Capital

FY, 2019FY, 2018FY, 2017
Female (Managers)10.9%10%10.9%
Female (Non-Managers)35.6%36.8%35.6%
Male (Non-Managers)41.3%41.9%40.5%
Male (Managers)12.2%11.3%13%
Other0%0%0%

Teva Pharmaceuticals Employee Rating

3.71703 votes
Culture & Values
3.5
Work/Life Balance
3.5
Senior Management
3
Salary & Benefits
3.8
Career Opportunities
3.1
Source